The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

Hepatic FXR may act as a tumor suppressor in hepatocellular carcinoma (HCC) and is also associated with liver injury and cholestasis. Therefore, avoiding hepatic FXR antagonism is critical when ...

By that time the cholestasis was more pronounced, and there was slight focal or disseminated fatty degeneration. Neither hepatocellular necrosis nor evidence of reactive inflammation was found (Fig.

hepatocellular carcinoma cancer immunobiology immunogenetics immunotherapy ... For instance, in Patient 1, T5 and T10 appeared soft and white, while other lesions looked yellow with cholestasis; in ...

Research indicates that after 5 years of UDCA therapy, the incidence of liver decompensation in PBC patients is between 3.81% and 4.31%, while the rate of hepatocellular carcinoma development ...

People who used lipophilic (fat-soluble) statins like atorvastatin and simvastatin had the greatest outcomes and ...

For patients with chronic liver disease, statin use is associated with a reduced risk for hepatocellular carcinoma (HCC) and ...

Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships Global incidence of hepatocellular carcinoma ...

Direct-acting antivirals (DAAs) have dramatically changed the landscape of chronic hepatitis C virus (HCV) treatment and ...

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, accounts for about 75–85% of all liver cancer ...